Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
-1.26 |
-1.03 |
0.23 |
18.25% |
2024-03-04 |
2023-12 |
-1.65 |
-1.5 |
0.15 |
9.09% |
2024-03-04 |
2023-12 |
-1.65 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-1.5 |
-1.6 |
-0.1 |
-6.67% |
2023-11-09 |
2023-09 |
-1.5 |
N/A |
N/A |
N/A |
2023-08-11 |
2023-06 |
-1.3 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-11 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-13 |
Credit Suisse |
Upgrade |
Outperform |
Outperform |
2023-08-10 |
Capital One |
Upgrade |
|
Overweight |
2023-06-11 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-05-14 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-05-14 |
Credit Suisse |
Upgrade |
Outperform |
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-02-07 |
CARLYLE GROUP, INC. |
Unknown |
0.00 |
Purchase |
2023-04-12 |
EMSTER KURT VON |
Director |
21.18K |
Sale |
2023-04-13 |
FRENCH ANNA LOUISE |
Director |
23.75K |
Sale |
2023-10-12 |
LIS WILLIAM |
Director |
53.52K |
Sale |
2024-03-11 |
MAHAL JEETINDER SINGH |
Chief Operating Officer |
25.01K |
Sale |
2022-10-11 |
MARTELL RONALD A |
Chief Executive Officer |
506.25K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Velan Capital Investment Management LP |
11.22M |
15.37M |
10.13% |
2023-06-29 |
BVF Inc. |
9.90M |
13.56M |
8.93% |
2023-06-29 |
Carlyle Group Inc. |
8.76M |
12.00M |
7.91% |
2023-06-29 |
Qiming U.s. Ventures Management, Llc |
8.52M |
11.67M |
7.69% |
2023-06-29 |
Soleus Capital Management, L.P. |
7.78M |
10.65M |
7.02% |
2023-06-29 |
Franklin Resources, Inc. |
4.50M |
6.17M |
4.06% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.37M |
3.25M |
2.14% |
2023-07-30 |
Franklin Strategic Series-Franklin Biotechnology Discove |
1.44M |
2.17M |
1.30% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.16M |
1.59M |
1.05% |
2023-05-30 |
Fidelity Extended Market Index Fund |
467.02K |
723.88K |
0.42% |
2023-05-30 |
Fidelity Total Market Index Fund |
243.15K |
376.88K |
0.22% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
187.63K |
290.83K |
0.17% |
Split |
Date |
1 : 10 |
2024-01-04 |